

NIH Public Access

Author Manuscript

J Org Chem. Author manuscript; available in PMC 2013 March 02.

Published in final edited form as:

J Org Chem. 2012 March 2; 77(5): 2543–2547. doi:10.1021/jo202537e.

Me₃(OMe)*t*BuXPhos: A Surrogate Ligand for Me₄*t*BuXPhos in Palladium-Catalyzed C–N and C–O Bond-Forming Reactions

Satoshi Ueda, Siraj Ali, Brett P. Fors, and Stephen L. Buchwald*

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139

Abstract

A new biaryl phosphine ligand, $Me_3(OMe)$ /BuXPhos (L3), was designed as a surrogate for Me_4 /BuXPhos (L1). The $Me_3(OMe)$ /BuXPhos could be prepared in a chromatography-free manner from inexpensive and readily available 2,3,6-trimethylphenol. Comparative studies demonstrated that a catalyst based on $Me_3(OMe)$ /BuXPhos displayed the same reactivity as a catalyst based on Me_4 /BuXPhos for Pd-catalyzed C–N and C–O bond-forming processes.

Keywords

Palladium; Phosphine Ligand; N-Arylation; O-Arylation

Me₄/BuXPhos (**L1**) is a useful ligand in Au-catalyzed carbocyclization1 and Pd-catalyzed arylation reactions of nitrogen/oxygen nucleophiles, including amides,² benzimidazoles,³ phenols⁴ and water.⁵ We recently demonstrated that the combination of Pd and **L1** was the most effective catalyst system for the highly N²-selective arylation of 1,2,3-triazoles⁶ and completely N¹-selective arylation of unsymmetric imidazoles.⁷ **L1** is synthesized from 1,2,3,4-tetramethylbenzene via dibromination and then a one-pot biaryl phosphine synthesis protocol, which proceeds through a benzyne intermediate.^{4,5} However, the high cost and limited availability of the 1,2,3,4-tetramethylbenzene⁸ could potentially prevent the utilization of Pd/**L1** systems, as well as the future development of methods using **L1** as a supporting ligand for various metals. To circumvent this problem, the development of an inexpensive and robust alternative to **L1** is highly desirable.

Mechanistic investigations by our group on Pd-catalyzed aryl amidation with L1 indicated that the 3-methyl substituent of the ligand restricts rotation of the Ar–P bond and fixes the Pd center over the triisopropylphenyl ring.^{2a} In addition, it was postulated that 6-methyl group of L1 increases conformational rigidity in the Pd-ligand complex and possibly accelerates the rate of reductive elimination.³ Based on these two features it was proposed that the utility of L1 was superior to that of non-methylated ligand *t*BuXPhos (L2) in several Pd-catalyzed C–N bond-forming reactions.^{2,6–7} We felt that ligand, L3, which possesses both 3- and 6-methyl substitutents and is accessible from inexpensive and readily available 2,3,6-trimethylphenol⁹ might be a suitable surrogate for L1. Herein, we report a synthesis of L3 and its utilization in the Pd-catalyzed arylation reactions of nitrogen and oxygen nucleophiles.

sbuchwal@mit.edu.

Supporting Information Available: Copies of ¹H and ¹³C NMR spectra. This material is available free of charge via the Internet at http://pubs.acs.org.

The synthesis of L3 is described in Scheme 1. Dibromide 2 was prepared from 2,3,6trimethylphenol via dibromination and O-methylation. Notably, both 1 and 2 were crystalline solids and could be isolated in pure form without chromatography. Dibromide 2 was treated with Mg and 2,4,6-triisopropylphenyl magnesiumbromide in THF at 60 ° C for 1.5 h and then allowed to react with CuCl and ClP(*t*Bu)₂ to give L3 in 61% yield. ¹H NMR analysis showed that L3 was an approximately a 1:1 mixture of two regioisomers, suggesting that addition of the aryl Grignard reagent to the benzyne generated from 2 was unselective.

In order to compare the activity of the Pd/L1 and Pd/L3 systems, the reaction progress of the N-arylation of nitrogen heterocycles was investigated (Schemes 2 and 3). Previously, the N-arylation of 4-methylimidazole and bromobenzene with Pd/L1 gave *N*-arylated product **3a** in 95% yield with complete N¹-selectivity.⁷ The same N-arylation reaction using Pd/L3 showed similar progress and the *N*-arylated product was obtained in 96% yield with complete N¹-selectivity, almost identical yields (90% with L1, 89% with L3) and N²-selectivity (N²:N¹ = 97:3 for both L1 and L3) were observed for the N-arylation of 1,2,3-triazole.⁶ These results demonstrate that a catalyst based on L3 shows identical reactivity to a catalyst based on L1, indicating that it is excellent surrogate for C–N cross-coupling reactions.

We next explored the scope of the Pd/L3 system using variety of aryl halides and N/Onucleophiles (Scheme 4). We found that the use of Pd/L3 gave comparable yields to those obtained with Pd/L1 in all reactions examined. It should be noted that N^{1} -aryl-4methylimidazoles **3c** and **3d**, which are key intermediate for the synthesis of GSK2137305¹⁰ and nilotinib (Tasigna®)¹¹ were prepared in high yield as single regioisomers at 0.3 or 0.5 mol % Pd loadings.

In summary, we have designed and synthesized a new biaryl phosphine ligand, Me₃(OMe)*t*BuXPhos (L3). The ligand L3 could be prepared in a chromatography-free manner from inexpensive and readily available 2,3,6-trimethylphenol. Comparative studies of L1 and L3 demonstrated that L3 could indeed serve as a surrogate for the Me₄*t*BuXPhos (L1). We expect wide use and large-scale application of L3 as an efficient substitute for L1 in a variety of Pd-catalyzed C–N and C–O bond-forming reactions.

Experimental Section

General Information

Pd₂(dba)₃ and Pd(OAc)₂ was purchased from Strem Chemicals Inc. Anhydrous tribasic potassium phosphate was stored in a glovebox. Small portions were removed and stored in a desiccator for up to 2 weeks (All reactions were set-up outside of the glovebox). L1^{4a} was prepared by literature procedure. Reactions were monitored by GC and thin-layer chromatography (TLC) using UV light. Flash chromatography was performed using silica gel (230–400 mesh). All ¹H NMR experiments are reported in δ units, parts per million (ppm), and were measured relative to the signals for residual chloroform (7.26 ppm) or dimethylsulfoxide-*d6* (2.50 ppm) in the deuterated solvent. All ¹³C NMR spectra are reported in ppm relative to deuterochloroform (77.23 ppm) or dimethylsulfoxide-*d6* (39.52 ppm), unless otherwise stated, and all were obtained with 1H decoupling. The pure compounds are estimated to be 95% pure as determined by ¹H NMR or GC analysis.

3,4-Dibromo-2,5,6-trimethylphenol (1)—To a stirred solution of 2,3,6-trimethylphenol (20.4 g, 150 mmol) and I₂ (381 mg, 1.5 mmol) in CH₂Cl₂ (150 mL), Br₂ (17.0 mL, 330 mmol) was added dropwise (1 drop/1 sec) at room temperature. After the addition of Br₂ was complete, the reaction mixture was stirred at room temperature for 3 h then a saturated

aqueous solution of Na₂SO₃ (150 mL) was added to quench the residual Br₂. The organic phase was separated and washed with brine, dried over MgSO₄, and concentrated in vacuo to give a white solid which was triturated with hexanes and collected by filtration. The white solid was dried in vacuo to give 40.1 g (92% yield) of the title compound. Mp 142–144 °C; ¹H NMR (400 MHz, CDCl₃): δ 4.73 (s, 1H), 2.43 (s, 3H), 2.40 (s, 3H), 2.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 151.23, 136.5, 125.3, 123.3, 122.7, 119.4, 22.3, 18.3, 13.7; IR (film) vmax: 3376, 1699, 1652, 1558, 1541, 1456, 1388, 1290, 1199, 1081, 970, 784, 731 cm⁻¹; Anal. Calcd. For C₉H₁₀Br₂O: C, 36.77; H, 3.43. Found: C, 36.63; H, 3.39.

1,2-Dibromo-4-methoxy-3,5,6-trimethylbenzene (2)—A 250 mL round bottom flask, which was equipped with a stir bar, was charged with 3,4-dibromo-2,5,6-trimethylphenol (14.7 g, 50 mmol) and K₂CO₃ (8.3 g, 60 mmol). Acetone (80 mL) and dimethyl sulfate (5.68 mL, 60 mmol) were added to the mixture and then the flask was equipped with a reflux condenser. The reaction mixture was stirred at 75 °C for 6 h. After cooling to room temperature, an aqueous KOH solution (2.0 M, 100 mL) was added and the mixture was stirred at room temperature for 20 min. The reaction mixture was concentrated to remove acetone and then, extracted with Et₂O, washed with brine, dried over MgSO₄ and concentrated under reduced pressure to give the title compound as a white solid (15.0 g, 97% yield, GC purity of 99.5% area %). Mp 63–65 °C; ¹H NMR (400 MHz, CDCl₃): δ 3.65 (s, 3H), 2.44 (s, 3H), 2.42 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.3, 137.1, 131.2, 130.3, 125.6, 123.4, 60.5, 22.2, 18.6, 14.1; IR (film) vmax: 2924, 1652, 1540, 1449, 1375, 1213, 1092, 1002, 972, 902, 755, 668 cm⁻¹; Anal. Calcd. For C₁₀H₁₂Br₂O: C, 38.99; H, 3.93. Found: C, 38.82; H, 3.86.

Di-*tert*-butyl(2',4',6'-triisopropyl-5-methoxy-3,4,6-trimethyl[1,1'-biphenyl]-2yl)phosphine/di-*tert*-butyl(2',4',6'-triisopropyl-4-methoxy-3,5,6-trimethyl-[1,1'biphonyl]-2-yl)phosphine (1.3)—An even dried 250 mL round bettern flask which we

biphenyl]-2-yl)phosphine (L3)-An oven-dried 250 mL round bottom flask, which was equipped with a stir bar and charged with Mg shavings (1.02 g, 42 mmol) was fitted with a reflux condenser, a glass stopper and a rubber septum. The flask was purged with argon and then 2-bromo-1,3,5-triisopropylbenzene (5.07 mL, 20 mmol) and anhydrous THF (40 mL) were added via syringe. The reaction mixture was heated to 60 °C and 1,2-dibromoethane (50 µL) was added via syringe. The reaction was stirred at 60 °C for 1.5 h. 1,2-Dibromo-4methoxy-3,5,6-trimethylbenzene (6.16 g, 20 mmol) was added portion wise to the reaction mixture over 30 min period under a stream of argon. After the addition of 1,2-dibromo-4methoxy-3,5,6-trimethylbenzene was complete, the reaction mixture was stirred at 60 °C for 1.5 h. The reaction mixture was cooled to room temperature and CuCl (1.98 g, 20 mmol) and CIPtBu2 (4.6 mL, 24 mmol) were quickly added under a stream of argon. The reaction mixture was heated to reflux at 75 °C for 30 h. The reaction mixture was cooled to room temperature, diluted with Et₂O, washed three times with 30% NH₄OH, dried over MgSO₄ and concentrated under reduced pressure to give a pale yellow crude oil. The crude oil was diluted with EtOAc (5 mL) and then, MeOH (50 mL) was added. The mixture was cooled to 0 °C and the white precipitate that had formed was collected by filtration, washed two times with cold MeOH and dried in vacuo to yield a white powder (6.03 g, 61% yield, mp 130-132 °C) as an approximately 1:0.98 mixture of two isomers as determined by methoxy proton signals (methoxy proton signal of major isomer: 3.75 ppm, minor isomer: 3.68 ppm). ¹H NMR (400 MHz, CDCl₃) & 6.95/6.94 (s, 2H), 3.76/3.68 (s, 3H), 2.97-2.86 (m, 1H), 2.57/2.53 (s, 3H), 2.48-2.33 (m, 2H), 2.26/2.20 (s, 3H), 1.76/1.73 (s, 3H), 1.31-1.25 (m, 6H), 1.23-1.19 (m, 6H), 1.16-1.09 (m, 18H), 0.93/0.89 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) & 157.7, 155.8, 150.0, 149.6, 147.5, 147.5, 146.5, 146.5, 146.2, 141.6, 141.6, 138.1, 137.8, 137.7, 136.1, 136.0, 134.0, 133.9, 130.5, 130.4, 129.0, 128.9, 127.6, 120.7, 120.6, 59.7, 59.6, 34.7, 34.6, 34.3, 34.3, 34.2, 32.8, 32.6, 31.0, 31.0, 31.0, 26.2, 26.2, 25.5, 25.5, 24.8, 24.7, 24.7, 24.7, 24.4, 24.4, 21.9, 21.9, 21.1, 21.0. (Observed complexity is due

to C-P splitting); ³¹P NMR (121 MHz, CDCl₃): δ 39.17, 38.16; IR (film) vmax: 2956, 2362, 1542, 1461, 1381, 1311, 1208, 1166, 1090, 1011, 911 cm⁻¹; Anal. Calcd. For C₃₃H₅₃OP: C, 79.79; H, 10.75. Found: C, 79.71; H, 10.69.

4-Methyl-1-phenyl-1H-imidazole (3a)—An oven-dried vial was equipped with a magnetic stir bar and charged with $Pd_2(dba)_3$ (6.9 mg, 0.0075 mmol) and L1 or L3 (0.018 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Anhydrous toluene (0.83 mL) and anhydrous 1,4-dioxane (0.17 mL) were added via syringe The resulting dark purple mixture was stirred at 120 °C for 3 min, at this point the color of the mixture turned to redbrown. A second oven-dried vial, which was equipped with a stir bar, was charged with 4methylimidazole (98 mg, 1.2 mmol) and K₃PO₄ (424 mg, 2.0 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times) and then bromobenzene (106 μ L, 1.0 mmol) and the preheated catalyst solution were added via syringe to the second vial. The reaction mixture was heated at 120 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified via flash chromatography (EtOAc/MeOH, 50:1) to provide the title compound as a pale-vellow solid (152 mg, 96% (with L3)), mp 60 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 1.6 Hz, 1H), 7.36-7.29 (m, 2H), 7.25-7.17 (m, 3H), 6.89 (s, 1H), 2.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) & 139.4, 137.3, 134.4, 129.7, 126.9, 120.8, 114.4, 13.6; IR (film) vmax 3385, 3108, 2921, 1599, 1507, 1448, 1392, 1366, 1291, 1241, 1070, 1003, 969, 817, 759, 692 cm⁻¹; Anal. Calcd. For C₁₀H₁₀N₂: C, 75.92; H, 6.37. Found: C, 76.04; H, 6.33.

2-Phenyl-1,2,3-triazole (3b)—An oven-dried vial was equipped with a magnetic stir bar and charged with Pd₂(dba)₃ (6.9 mg, 0.0075 mmol) and L1 or L3 (0.018 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Anhydrous toluene (1.0 mL) was added via syringe and the resulting dark purple mixture was stirred at 120 °C for 3 min, at this point the color of the mixture turned to red-brown. A second oven-dried vial, which was equipped with a stir bar, was charged with K₃PO₄ (424 mg, 2.0 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times) and then bromobenzene (106 μ L, 1.0 mmol), 1,2,3-triazole (70 μ L, 1.2 mmol) and the pre-heated catalyst solution were added via syringe to the second vial. The reaction mixture was heated at 120 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified via flash chromatography (Hexanes/EtOAc, 9:1) to provide the title compound as colorless oil (129 mg, 89% (with L3)). ¹H NMR (400 MHz, CDCl3) & 8.12-8.06 (m, 2H), 7.80 (s, 2H), 7.51-7.44 (m, 2H), 7.38-7.32 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 140.0, 135.6, 129.4, 127.6, 119.1; IR (film) vmax 3128, 3059, 2362, 1745, 1598, 1500, 1410, 1376, 1259, 1152, 1069, 953, 820, 757, 692, 668, 510, 455 cm⁻¹; Anal. Calcd. For C8H7N3: C, 66.19; H, 4.86. Found: C, 66.23; H, 4.91.

3-(4-(4-Methyl-1H-imidazol-1-yl)phenyl)-1,4-diazaspiro[4.4]non-3-en-2-one (3c)

—An oven-dried vial was equipped with a magnetic stir bar and charged with $Pd_2(dba)_3$ (4.6 mg, 0.005 mmol) and **L1** or **L3** (0.01 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of 3 times). Anhydrous toluene (0.6 mL) was added via syringe and the resulting dark purple mixture was stirred at 130 °C for 3 min. A second oven-dried vial which was equipped with a stir bar was charged with 3-(4-chlorophenyl)-1,4-diazaspiro[4.4]non-3-en-2-one⁷ (249 mg, 1.0 mmol), 4-methylimidazole (164 mg, 2.0 mmol) and K₃PO₄ (424 mg, 2.0 mmol). The vial

was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). The pre-heated catalyst solution (0.18 mL, 0.3 mol% Pd) was transferred to the second vial via syringe and then toluene (0.5 mL) and dioxane (0.5 mL) were added (a total 1.18 mL of solvent). The reaction mixture was heated at 130 °C for 6 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified via flash chromatography (EtOAc-MeOH, 15:1) to provide the title compound as a white solid (268 mg, 91% (with L3)), mp 194–195 °C. ¹H NMR (400 MHz, DMSO-*d6*) δ 10.09 (s, 1H), 8.42 (d, *J* = 8.8 Hz, 2H), 8.26 (d, *J* = 1.2 Hz, 1H), 7.74 (d, *J* = 8.8 Hz, 2H), 7.53 (s, 1H), 2.17 (s, 3H), 2.00-1.77 (m, 8H); ¹³C NMR (100 MHz, DMSO-*d6*) δ 164.1, 158.8, 138.9, 138.8, 134.7, 129.4, 128.5, 119.3, 113.8, 89.6, 37.1, 23.9, 13.6; IR (film) v3max 3854, 3745, 3158, 3050, 2962, 2360, 1704, 1606, 1518, 1442, 1254, 1191, 1063, 963, 848, 752, 540 cm⁻¹; Anal. Calcd. For C₁₇H₁₈N₄O: C, 69.37; H, 6.16. Found: C, 69.21; H, 6.12.

3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline (3d)-An oven-dried vial was equipped with a magnetic stir bar and charged with Pd₂(dba)₃ (2.3 mg, 0.0025 mmol) and L1 or L3 (0.0025 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Then, anhydrous toluene (0.5 mL) was added via syringe. This dark purple mixture was stirred at 120 °C for 3 min. The color of the mixture turns to dark brown after 3 min. A second ovendried vial which was equipped with a stir bar was charged with 3-amino-5bromobenzotifluoride (240 mg, 1.0 mmol), 4-methylimidazole (197 mg, 2.4 mmol) and K_3PO_4 (424 mg, 2.0 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of 3 times). The preheated catalyst solution, followed by anhydrous toluene (0.5 mL) and tBuOH (1.0 mL), were added via syringe to the second vial (a total 2 mL of toluene-tBuOH 1:1 solution). The reaction was heated at 120 °C for 8 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over MgSO₄, concentrated in vacuo and purified via flash chromatography (Et₂O/EtOAc/MeOH, 125:125:1) to provide the title compound as a white solid (219 mg, 91% (with L3)), mp 125 °C. ¹H NMR (400 MHz, DMSO-*d6*) & 8.09 (d, J=1.2 Hz, 1H), 7.35 (s, 1H), 6.99 (s, 1H), 6.96 (s, 1H), 6.85 (s, 1H), 5.91 (s, 2H), 2.16 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d6*) δ 150.9, 138.5, 134.8, 131.3 (q, J= 38 Hz), 124.1 (q, J= 272 Hz), 114.2, 107.9, 103.3 (q, J= 4 Hz), 13.5; IR (film) vmax 3854, 3745, 3414, 3215, 2362, 1620, 1509, 1412, 1328, 1293, 1254, 1199, 1158, 1115, 843, 807, 735, 691, 621 cm⁻¹; Anal. Calcd. For C₁₁H₁₀F₃N₃: C, 54.77; H, 4.18. Found: C, 54.61; H, 4.11.

2-(1-(6-Methoxypyridin-2-yl)-1*H***-imidazol-4-yl)acetonitrile (3e)**—An oven-dried vial was equipped with a magnetic stir bar and charged with $Pd_2(dba)_3$ (2.3 mg, 0.0025 mmol) and L1 or L3 (0.005 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Anhydrous toluene (0.41 mL) and anhydrous 1,4-dioxane (0.19 mL) were added via syringe. The resulting dark purple mixture was stirred at 120 °C for 3 min, at this point the color of the mixture turned to red brown. A second oven-dried vial, which was equipped with stir bar, was charged with 4-cyanomethylimidazole (64 mg, 0.6 mmol) and K₃PO₄ (212 mg, 1.0 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times) and then 6-bromo-2-methoxypyridine (61 μ L, 0.5 mmol) and the preheated catalyst solution were added via syringe to the second vial. The reaction mixture was heated at 120 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified via flash

chromatography (EtOAc) to provide the title compound as a white solid (94 mg, 87% (with **L3**)), mp 77–78 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, J= 1.2 Hz, 1H), 7.63 (t, J= 8.0 Hz, 1H), 7.58 (s, 1H), 6.84 (d, J= 7.6 Hz, 1H), 6.24 (d, J= 8.4 Hz, 1H), 3.91 (s, 3H), 3.73 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 146.5, 141.2, 135.2, 133.0, 117.4, 114.0, 109.2, 103.6, 53.8, 17.9; IR (film) vmax 3397, 2954, 1614, 1580, 1481, 1452, 1421, 1321, 1253, 1091, 1035, 1000, 860, 793 cm⁻¹; Anal. Calcd. For C₁₁H₁₀N₄O: C, 61.67; H, 4.71. Found: C, 61.65; H, 4.77.

1-(Pyrimidin-5-yl)-1*H*-benzimidazole (3f)—An oven-dried vial was equipped with a magnetic stir bar and charged with $Pd_2(dba)_3$ (2.3 mg, 0.0025 mmol) and L1 or L3 (0.005 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Anhydrous toluene (0.3 mL) was added via syringe. The resulting dark purple mixture was stirred at 120 °C for 3 min, at this point the color of the mixture turned to red-brown. A second oven-dried vial, which was equipped with a stir bar, was charged with benzimidazole (142 mg, 1.2 mmol), 5bromopyrimidine (159 mg, 1.0 mmol) and K₃PO₄ (424 mg, 2.0 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times) and then the pre-heated catalyst solution, toluene (0.53 mL) and dioxane (0.17 mL) were added to the second vial. The reaction mixture was heated at 120 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over $MgSO_4$ and concentrated in vacuo. The crude product was purified via flash chromatography (EtOAc/MeOH, 15:1) to provide the title compound as a white solid (190 mg, 97% (with L3)), mp 137–139 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.26 (s, 1H), 8.95 (s, 2H), 8.07 (s, 1H), 7.86-7.81 (m, 1H), 7.47-7.41 (m, 1H), 7.37-7.31 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 157.7, 151.9, 144.1, 141.3, 133.0, 132.0, 124.7, 123.8, 121.2, 109.6; IR (film) vmax 3745, 3065, 2362, 1698, 1652, 1558, 1497, 1464, 1429, 1291, 1245, 1208, 881, 725, 615 cm⁻¹; Anal. Calcd. For C₁₁H₈N₄: C, 67.34; H, 4.11. Found: C, 67.42; H, 4.20.

N-(3-Methoxyphenyl)benzamide (3g)—An oven-dried vial was equipped with a magnetic stir bar and charged with benzamide (145 mg, 1.2 mmol), K_3PO_4 (254 mg, 1.2 mmol), $Pd_2(dba)_3$ (4.6 mg, 0.005 mmol) and L1 or L3 (0.02 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Bromobenzene (106 µL, 1.0 mmol) and *t*BuOH (2.0 mL) were added via syringe and the reaction mixture was heated at 110 °C for 16 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified via flash chromatography (hexanes/EtOAc, 3:1) to provide the title compound as a white solid (206 mg, 91% (with L3)), mp 117–119 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 7.81-7.75 (m, 2H), 7.45-7.37 (m, 2H), 7.33-7.26 (m, 2H), 7.19-7.11 (m, 2H), 6.67-6.61 (m, 1H), 3.67 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.5, 160.1, 139.4, 134.9, 131.7, 129.6, 128.6, 127.2, 112.9, 110.5, 106.3, 55.2; IR (film) vmax 3304, 1652, 1607, 1540, 1492, 1455, 1420, 1305, 1276, 1200, 1160, 1046, 854, 775, 690 cm⁻¹; Anal. Calcd. For C₁₄H₁₃NO₂: C, 73.99; H, 5.77. Found: C, 73.73; H, 5.75.

2-Methyl-5-phenoxybenzo[d]thiazole (3i)—An oven-dried vial was equipped with a magnetic stir bar and charged with 5-chloro-2-methylbenzothiazole (184 mg, 1.0 mmol), phenol (113 mg, 1.2 mmol), K_3PO_4 (424 mg, 2.0 mmol), $Pd(OAc)_2$ (4.5 mg, 0.02 mmol) and **L1** or **L3** (0.03 mmol). The vial was sealed with a screw-cap septum, and then evacuated and backfilled with argon (this process was repeated a total of three times). Toluene (1.5 mL) was added via syringe and the reaction mixture was heated at 100 °C for 16 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed

with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified via flash chromatography (hexanes/EtOAc, 7:1) to provide the title compound as colorless oil (224 mg, 93% (with **L3**)). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 8.8 Hz, 1H), 7.57 (d, *J* = 2.0 Hz, 1H), 7.37-7.30 (m, 2H), 7.14-7.02 (m, 4H), 2.81 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.8, 157.4, 156.3, 154.6, 130.3, 129.9, 123.6, 122.1, 119.0, 117.3, 112.1, 20.3; IR (film) vmax 3064, 2922, 1590, 1558, 1522, 1489, 1453, 1311, 1266, 1216, 1169, 1133, 1069, 1002, 950, 872, 810, 752, 693, 643 cm⁻¹; Anal. Calcd. For C₁₄H₁₁NOS: C, 69.68; H, 4.59. Found: C, 69.63; H, 4.64.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work is supported by National Institutes of Health (GM58160). We gratefully acknowledge Dr. Xiaohua Huang who first prepared L3. S.U. thanks the Japan Society for the Promotion of Sciences (JSPS) for a Postdoctoral Fellowship for Research Abroad. S.A. thanks the MIT UROP program for support. B.P.F. thanks Bristol-Myers Squibb for a graduate fellowship.

References

- 1. Barabé F, Levesque P, Korobkov I, Barriault L. Org Lett. 2011; 13:5580. [PubMed: 21916520]
- (a) Ikawa T, Barder TE, Biscoe MR, Buchwald SL. J Am Chem Soc. 2007; 129:13001. [PubMed: 17918833] (b) Fors BP, Krattiger P, Strieter E, Buchwald SL. Org Lett. 2008; 10:3505. [PubMed: 18620415] (c) Nodwell M, Pereira A, Riffell JL, Zimmerman C, Patrick BO, Roberge M, Andersen RJ. J Org Chem. 2009; 74:995. [PubMed: 19128042]
- 3. Anderson KW, Tundel RE, Ikawa T, Altman RA, Buchwald SL. Angew Chem Int Ed. 2006; 45:6523.
- 4. (a) Burgos CH, Barder TE, Huang X, Buchwald SL. Angew Chem Int Ed. 2006; 45:4321.(b) Štefko M, Hocek M. Synthesis. 2010:4199.(c) Štefko M, Slavitínská L, Klepetáøová B, Hocek M. J Org Chem. 2011; 76:6619. [PubMed: 21739971]
- Anderson KW, Ikawa T, Tundel RE, Buchwald SL. J Am Chem Soc. 2006; 128:10694. [PubMed: 16910660]
- 6. Ueda S, Su M, Buchwald SL. Angew Chem Int Ed. 2011; 50:8944.
- 7. Ueda S, Su M, Buchwald SL. J Am Chem Soc. 2012; 134:700. [PubMed: 22126442]
- 8. For example, 301 usd/25 g by AlfaAesar (Oct. 2011)
- 9. For example, 346 usd/5 kg by Sigma-Aldrich (Oct. 2011)
- Graham JP, Langlade N, Northall JM, Roberts AJ, Whitehead AJ. Org Process Res Dev. 2011; 15:44.
- 11. Breitenstein, W.; Furet, P.; Jacob, S.; Manley, PW. WO. 2004005281. 2004.







Figure 1. Structures of biaryl phosphine ligands




Scheme 1. Preparation of L3


NIH-PA Author Manuscript







Scheme 3. Comparison of catalysts based on L1 and L3 for the N-arylation of 1,2,3-triazole



Scheme 4.

Comparison of catalysts based on **L1** and **L3** for the N- and O-arylation reactions^{*a*} ^{*a*} Reactions were carried out in 1.0 mmol scale. Isolated yields, average of two runs. ^{*b*} Condition: $Pd_2(dba)_3$ (**L**/Pd = 1:1), 4-methylimidazole (2 mmol), K_3PO_4 (2 mmol), toluene-dioxane (1:1), 130 ° C, 6 h. ^{*d*} Condition: $Pd_2(dba)_3$ (**L**/Pd = 1:1), 4-methylimidazole (2.4 mmol), K_3PO_4 (2 mmol), toluene-*t*BuOH (1:1), 120 ° C, 8 h. ^{*d*} Condition: $Pd_2(dba)_3$ (**L**/Pd = 1:1), imidazole derivative (1.2 mmol), K_3PO_4 (2 mmol), toluene-dioxane (5:1), 120 ° C, 5 h. ^{*e*} Condition: $Pd_2(dba)_3$ (**L**/Pd = 1:2.5), benzamide (1.2 mmol), K_3PO_4 (1.2 mmol), *t*BuOH, 110 ° C, 16 h. ^{*f*} Condition: $Pd_2(dba)_3$ (**L**/Pd = 1:2), KOH (3 mmol), H₂O-dioxane (1:1), 100 ° C, 16 h. ^{*g*} Condition: $Pd(OAc)_2$ (**L**/Pd = 1:1.5), phenol (1.2 mmol), K_3PO_4 (2 mmol), toluene, 100 ° C, 16 h.